3,6′-Disinapoyl sucrose modulates GALE-mediated metabolic reprogramming to alleviate asthmatic airway inflammation
International Immunopharmacology · 2025
DOI: 10.1016/j.intimp.2025.115463 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunopharmacology, 2025. Verfasst von Haisong Jiang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anesthesiology, Yanbian University Medical College, Yanji 133002, PR China; Jilin Key Laboratory for Immune and Targeting Research on C…. Hauptthemen laut MEDLINE: Asthma, UDPglucose 4-Epimerase, Sucrose, Anti-Asthmatic Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 24 Literaturangaben. Gefördert von: Jilin Province Health Commission, National Natural Science Foundation of China.
Abstract (Originalsprache)
BACKGROUND: Asthma is a heterogeneous disease characterized by chronic airway inflammation and metabolic dysregulation. Recent studies highlight the role of glycolysis and oxidative phosphorylation (OXPHOS) imbalance in asthma pathogenesis, yet the underlying molecular mechanisms remain unclear. UDP-galactose-4-epimerase (GALE), a key enzyme in galactose metabolism, has not been previously explored in asthma. PURPOSE: This study aimed to identify asthma-associated metabolic genes and investigate the therapeutic potential of 3,6'-Disinapoyl Sucrose (DISS), a natural compound, in modulating GALE-mediated metabolic reprogramming. RESULTS: Weighted Gene Co-Expression Network Analysis (WGCNA) of bronchial epithelial datasets (GSE43696, GSE147878, GSE143303) identified 475 asthma-associated genes enriched in carbohydrate metabolism. Intersection with glycolysis/OXPHOS hallmark genes revealed GALE as a key candidate, validated by machine learning (SVM-RFE, RF, LASSO) and multi-dataset analysis. GALE expression correlated with severe and neutrophilic asthma subtypes. Virtual screening prioritized DISS as a GALE inhibitor (-14.91 kcal/mol), which suppressed glycolysis (reduced ECAR, PFK, PKM, LDHA), restored redox balance (increased SOD/CAT, decreased MDA), and mitigated mitochondrial dysfunction (restored ΔΨm, reduced mtROS) in HDM-stimulated BEAS-2B cells. In vivo, DISS attenuated airway inflammation (reduced IL-4, IL-5, IL-13, IgE), mucus hypersecretion, and pathological remodeling in HDM-induced asthmatic mice. CONCLUSION: GALE-driven metabolic reprogramming is a novel mechanism in asthma progression. DISS alleviates airway inflammation by targeting GALE, normalizing glycolysis, and reducing oxidative stress, offering a promising therapeutic strategy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Anesthesiology, Yanbian University Medical College, Yanji 133002, PR China; Jilin Key Laboratory for Immune and Targeting Research on Common Allergic Diseases, Yanbian University, Yanji 133002, PR China.
- Jilin Key Laboratory for Immune and Targeting Research on Common Allergic Diseases, Yanbian University, Yanji 133002, PR China; Department of Anatomy, Histology and Embryology, Yanbian University Medical College, Yanji…
Förderung
- Jilin Province Health Commission
- National Natural Science Foundation of China
Zitieren
APA
Jiang, H., Ding, N., Wang, Z., Shang, F., Yan, G., & Song, Y. (2025). 3,6′-Disinapoyl sucrose modulates GALE-mediated metabolic reprogramming to alleviate asthmatic airway inflammation. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2025.115463
Vancouver
Jiang H, Ding N, Wang Z, Shang F, Yan G, Song Y. 3,6′-Disinapoyl sucrose modulates GALE-mediated metabolic reprogramming to alleviate asthmatic airway inflammation. International Immunopharmacology. 2025. doi:10.1016/j.intimp.2025.115463
BibTeX
@article{Jiang2025,
author = {Jiang, Haisong and Ding, Ningpo and Wang, Zongqi and Shang, Fengxiang and Yan, Guanghai and Song, Yilan},
title = {3,6′-Disinapoyl sucrose modulates GALE-mediated metabolic reprogramming to alleviate asthmatic airway inflammation},
journal = {International Immunopharmacology},
year = {2025},
doi = {10.1016/j.intimp.2025.115463}
}
EUVIMED